企業レポート

小野薬品工業:パイプライン、製品、実績、潜在能力

Ono Pharmaceutical: Pipeline * Products * Performance * Potential

発行 Espicom Business Intelligence 商品コード 196747
出版日 ページ情報 英文 60 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
小野薬品工業:パイプライン、製品、実績、潜在能力 Ono Pharmaceutical: Pipeline * Products * Performance * Potential
出版日: 2011年04月30日 ページ情報: 英文 60 Pages
概要

2009年度は小野薬品工業にとって厳しい一年となりました。歴史的に同社は、競争があまりなく着実に売上を伸ばせるニッチ適応向け製品を販売しています。しかし近年の政府による価格の引き下げや様々な医療費用抑制策の導入が同社に打撃を与え、収益、所得ともに減少しました。複数の企業が市場の地位を強化するために合併に踏み切っています。小野薬品工業はまだ合併の意思を示していませんが、脆弱な立場に置かれています。

当レポートでは、小野薬品工業の企業戦略と将来見通しについて詳細に分析し、今後7年の製品予測、競合分析、パイプライン動向などをまとめ、概略下記の構成でお届けいたします。

エグゼクティブサマリー

  • イントロダクション
  • 財務実績
  • 企業戦略
    • 研究開発戦略
    • 主な契約
    • 従業員
  • 製品パフォーマンス予測
  • パイプライン分析
    • 中止された研究開発
  • 結論および今後の見通し

治療分野

R&Dパイプライン

心血管

  • 上市済み製品
    • Onoact
    • Opalmon
  • 研究開発プロジェクト

呼吸器

  • 上市済み製品
    • Onon
  • 研究開発プロジェクト

炎症

  • 上市済み製品
    • Foipan
    • Recalbon
  • 研究開発プロジェクト
    • ONO-5334

中枢神経系

  • 上市済み製品
    • Kinedak
  • 研究開発プロジェクト
    • ONO-4641
    • Remimazolam
    • Rivastach

代謝系

  • 上市済み製品
    • Glactiv
  • 研究開発プロジェクト

その他

  • 上市済み製品
    • Emend
  • 研究開発プロジェクト
    • Asimadoline
    • Carfilzomib
    • ONO-7643
    • ONO-8539

付録:財務実績

  • 2009年度実績

付録:主な契約

付録:インフラストラクチャー

  • 研究開発施設
  • 製造設備

付録:主な医薬品子会社・合弁会社

付録:製品インデックス

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

Abstract

Report Statistics

  • Publication Date: April 30th 2011
  • Total Number of Pages: 60
  • Available Formats: Web, PDF and Paper

Snapshot Ono Pharmaceuticals - Is a pharma merger required?

Fiscal 2009 was another difficult period for Ono. Historically, the company markets products for niche indications, ensuring low competition and steady sales. However, recent governmental price cuts and the implementation of various healthcare cost containment policies have hit the company hard, leading to declines in revenue and income. Ono is not the only Japanese company to be impacted by these factors, several of its competitors have entered into mergers to strengthen their position. In recent years, five major mergers have occurred in Japan to form Dainippon Sumitomo Pharma (Dainippon and Sumitomo Pharmaceutical), Astellas Pharma (Yamanouchi and Fujisawa), Mitsubishi-Tanabe Pharma (Mitsubishi Pharma and Tanabe), Daiichi Sankyo (Daiichi and Sankyo Pharmaceutical) and most recently, Kyowa Hakko Kirin (Kyowa Hakko and Kirin Brewery). Ono has not announced any merger intentions, which places the company in a vulnerable position.

If Ono is to emerge from this difficult period, the company will have to rapidly overhaul its product portfolio to market products with forecasted long-term growth. To this end, Ono established its Strategic Alliance division in 2007. This business segment is actively seeking collaborations around the globe in order to expand the pipeline through licensing agreements and bring candidate compounds to market more rapidly through research alliances. Agreements with Merck & Co, Novartis and Astellas have seen the pipeline bolstered by additions of Glactiv, Rivastach Patch and Recalbon, which are forecast to make strong contributions to company revenue. Drug development in Japan is focused on obtaining early approval for late-stage compounds, leveraged by results from multinational clinical trials and other international studies. Ono is also focused on acquiring commercialisation rights to new drug candidates. Gaining new drug approvals in Europe and the US, particularly in areas of unmet medical need, remains a key focus for Ono.

As one of the smaller players in the Japanese market, and certainly globally, a portfolio overhaul may not be sufficient to maintain Ono' s centuries old business. Ono should consider combining its aggressive licensing and collaborative strategy with a major pharmaceutical merger if it is to return to sales growth.

Sales of Top Ten Products (2008-2016)

But what' s in the pipeline?

For the full story on Ono Pharmaceutical' s challenges and opportunities order this important strategic analysis today

This new strategic report provides a detailed analysis of Ono Pharmaceutical' s competitive position and prospect for the futures. Using primary source information complemented by original 7-year product forecasts and competitive analysis, the report gives a complete and compelling oversight of the company, its products, pipeline and prospects.

Buyers of the web edition receive online access for one year via an easy-to-use interface with fast navigation and a full text search facility. All formats are the same price.

Report Statistics

  • Publication Date: April 30th 2011
  • Total Number of Pages: 60
  • Available Formats: Web, PDF and Paper

Table of Contents

Latest Results

EXECUTIVE SUMMARY

  • Introduction
  • Current Financial Position
    • Company Performance
    • Geographic Segment Performance
  • Company Strategy
    • R&D Strategy
    • Key Agreements
    • Employees
  • Product Performance Forecasts
  • Pipeline Analysis
    • Discontinued R&D
  • Conclusions/Outlook

THERAPEUTIC AREA FOCUS

R&D PIPELINE

CARDIOVASCULAR

  • Marketed Products
    • Onoact
    • Opalmon
  • R&D Projects

RESPIRATORY

  • Marketed Products
  • Onon
  • R&D Projects

INFLAMMATION

  • Marketed Products
    • Foipan
    • Recalbon
  • R&D Projects
    • ONO-5334

CNS

  • Kinedak
  • R&D Projects
    • ONO-4641
    • Remimazolam
    • Rivastach

METABOLISM

  • Marketed Products
    • Glactiv
  • R&D Projects

OTHERS

  • Marketed Products
    • Emend
  • R&D Projects
    • Asimadoline
    • Carfilzomib
  • ONO-7643
  • ONO-8539

APPENDIX 1 - FINANCIAL PERFORMANCE

  • Full Year Results 2009

APPENDIX 3 - KEY AGREEMENTS

  • Ansaris
  • Array BioPharma Inc
  • BioFocus DPI Plc
  • BioSeek
  • Dainippon Sumitomo Pharma
  • Dong-A Pharmaceuticals Co Ltd
  • Evotec
  • GlaxoSmithKline
  • Kyowa Hakko Kirin
  • Locus Pharmaceuticals Inc
  • Medarex Inc
  • Merck & Co
  • Nissan Chemical Industries Ltd
  • Novartis
  • PAION AG
  • Progenics Pharmaceuticals
  • Recordati
  • Sapphire Therapeutics Inc
  • Santen Pharmaceutical Co Ltd
  • Tioga Pharmaceuticals
  • UCB
  • Xention

APPENDIX 4 - INFRASTRUCTURE

  • Research and Development Facilities
  • Manufacturing Facilities

APPENDIX 5 - KEY PHARMACEUTICAL SUBSIDIARIES / JOINT VENTURES

  • Subsidiaries
  • Joint Ventures

APPENDIX 6 - PRODUCT INDEX

LIST OF TABLES:

  • Principal Operating Results
  • Recent Product Approvals
  • Opalmon/ProRenal Sales by Company (2008-2016)

LIST OF CHARTS:

  • Sales by Geographic Area, 2009
  • Sales of Top Ten Products (2008-2016)
  • Top Selling Products, 2009
  • Opalmon/ProRenal Sales (2008-2016)
  • Onon Sales (2008-2016)
  • Recalbon Sales (2009-2016)
  • Glactiv Sales (2009-2016)
  • Emend Sales (2009-2017)
  • Staybla Sales (2008-2016)
  • Carfilzomib Sales (2013-2016)
  • Sales, Costs and Operating Income
  • Profitability and Research Ratios
  • R&D Expenditure and Capital Expenditure
  • Current Assets, Liabilities and Ratio
  • Assets, Cash and Liquidity
  • Employees and Productivity
Back to Top